Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 13/20 | 0.48 |
| ▸ | MERTK | Q12866 | 12/20 | 0.48 |
| ▸ | FLT3 | P36888 | 11/20 | 0.48 |
| ▸ | GAS6 | Q14393 | 8/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 4/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13420488 | 1.00 | CSNK2A1 (0.53) | CSNK2A1TYRO3MERTKFLT3GAS6 | |
| SCHEMBL13311124 | 1.00 | CSNK2A1 (0.53) | CSNK2A1TYRO3MERTKFLT3GAS6 | |
| SCHEMBL3449243 | 0.88 | CSNK2A1 (0.46) | CSNK2A1TYRO3MERTKEGFRAXL | |
| SCHEMBL3448900 | 0.88 | CSNK2A1 (0.46) | CSNK2A1TYRO3MERTKEGFRAXL | |
| SCHEMBL3450065 | 0.88 | TYRO3 (0.52) | CSNK2A1TYRO3MERTKFLT3GAS6 | |
| SCHEMBL13421139 | 0.88 | TYRO3 (0.52) | CSNK2A1TYRO3MERTKFLT3GAS6 | |
| SCHEMBL3450061 | 0.88 | TYRO3 (0.52) | CSNK2A1TYRO3MERTKFLT3GAS6 | |
| SCHEMBL3450053 | 0.88 | TYRO3 (0.46) | CSNK2A1TYRO3MERTKFLT3GAS6 | |
| SCHEMBL3450052 | 0.88 | TYRO3 (0.46) | CSNK2A1TYRO3MERTKFLT3GAS6 | |
| SCHEMBL3450064 | 0.83 | CSNK2A1 (0.47) | CSNK2A1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | CSNK2A1 1858/4885TYRO3 2798/4885MERTK 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.